Matauro LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 173.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,270 shares of the company's stock after acquiring an additional 3,345 shares during the quarter. Matauro LLC's holdings in Johnson & Johnson were worth $874,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Meritas Wealth Management LLC acquired a new stake in Johnson & Johnson in the first quarter worth $204,000. Azzad Asset Management Inc. ADV acquired a new stake in Johnson & Johnson in the first quarter worth $6,351,000. ShankerValleau Wealth Advisors Inc. acquired a new stake in Johnson & Johnson in the first quarter worth $202,000. BigSur Wealth Management LLC raised its holdings in Johnson & Johnson by 0.9% in the first quarter. BigSur Wealth Management LLC now owns 8,418 shares of the company's stock worth $1,396,000 after purchasing an additional 79 shares during the period. Finally, New England Research & Management Inc. raised its holdings in Johnson & Johnson by 7.6% in the first quarter. New England Research & Management Inc. now owns 29,748 shares of the company's stock worth $4,933,000 after purchasing an additional 2,097 shares during the period. 69.55% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on JNJ. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Finally, Barclays dropped their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $170.88.
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Stock Up 0.2%
Shares of JNJ stock opened at $156.90 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm's fifty day moving average price is $153.84 and its two-hundred day moving average price is $153.71. The firm has a market capitalization of $377.52 billion, a P/E ratio of 23.59, a PEG ratio of 2.56 and a beta of 0.42.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
